Innovative Strategies for Second-Line Therapy for SCLC
Oncology0.75 AMA PRA Category 1 Credit(s) ™
July 25, 2025
July 25, 2026
Primary Audience:
Oncologists, oncology nurses, community oncologists, community oncology nurse practitioners, community oncology physician assistants and community oncology nurses.
Relevant Terms:
Oncology, SCLC
Narjust Florez, MD
Associate Director, Cancer Care Equity Program
Assistant Professor of Medicine, Dana-Farber Cancer Institute
Harvard Medical School
Dr. Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She completed her internal medicine residency at Rutgers New Jersey Medical School and her fellowship at the Mayo Clinic in Rochester, Minnesota, where she served as chief fellow from 2018 to 2019.
Dr. Florez's clinical interests include targeted therapies for lung cancer and addressing the unique aspects of survivorship in women with lung cancer. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. Beyond her clinical work, Dr. Florez is a leading researcher in cancer health disparities and has been recognized for her efforts to improve equitable access to high-quality cancer care for underserved populations.
In 2025, Dr. Florez was named a Health Equity Champion by the Boston Business Journal in their Innovators in Healthcare program, acknowledging her transformative work on initiatives such as SHAWL, FhINCH, and EQUAL, which aim to enhance access to care for underserved communities.
Dr. Florez also founded the Florez Lab in 2019, focusing on lung cancer research, social justice issues in medicine, and medical education. The lab aims to create a welcoming environment for medical trainees from historically underrepresented groups while improving care for vulnerable populations.
Julia Rotow, MD
Clinical Director, Lowe Center for Thoracic Oncology
Instructor in Medicine, Dana-Farber Cancer Institute
Harvard Medical School
Dr. Julia K. Rotow is a thoracic medical oncologist at Dana-Farber Cancer Institute and the Clinical Director of the Lowe Center for Thoracic Oncology. She is also an Assistant Professor of Medicine at Harvard Medical School.
Dr. Rotow completed her medical degree at the David Geffen School of Medicine at UCLA, followed by an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at the University of California, San Francisco.
Her clinical and research interests focus on developing targeted therapies and immunotherapies for oncogene-driven lung cancers, with a particular emphasis on addressing central nervous system metastases.
Beyond her clinical work, Dr. Rotow is an active researcher in the field of lung cancer treatment and is dedicated to advancing care for patients with advanced-stage disease. She is affiliated with both Dana-Farber Cancer Institute and Brigham and Women’s Hospital, where she continues to contribute to patient care and research.
| 1. | UTILIZE evidence-based strategies for sequencing second-line therapies in SCLC to improve patient outcomes | 2. | SELECT appropriate second-line therapy based on chemotherapy-free intervals (CTFI) |
| 3. | IMPLEMENT strategies to manage adverse events (AEs) associated with second-line therapies | 4. | UNDERSTAND the potential role of emerging agents for SCLC, including MOA, safety, and monitoring |
| 1. | UTILIZE evidence-based strategies for sequencing second-line therapies in SCLC to improve patient outcomes |
| 2. | SELECT appropriate second-line therapy based on chemotherapy-free intervals (CTFI) |
| 3. | IMPLEMENT strategies to manage adverse events (AEs) associated with second-line therapies |
| 4. | UNDERSTAND the potential role of emerging agents for SCLC, including MOA, safety, and monitoring |
TITLE: Innovative Strategies for Second-Line Therapy for SCLC: Harnessing the Power of a Social Peer-based Learning Environment to Optimize Outcomes
Release Date: July 25, 2025
Expiration Date: July 25, 2026
STATEMENT OF NEED
Small cell lung cancer (SCLC) remains a highly aggressive malignancy with limited treatment options in the second-line setting, contributing to poor patient outcomes. Advances in therapeutic strategies, including novel agents and treatment sequencing, offer new hope but also introduce complexities in clinical decision-making. Healthcare providers face challenges in selecting appropriate second-line therapies, managing treatment-related toxicities, and integrating emerging evidence into practice. This curriculum is designed to bridge these gaps, equipping participants with the latest clinical insights, evidence-based strategies, and practical tools to optimize outcomes for patients with SCLC.
EDUCATIONAL OBJECTIVES
- UTILIZE evidence-based strategies for sequencing second-line therapies in SCLC to improve patient outcomes
- IMPLEMENT strategies to manage adverse events (AEs) associated with second-line therapies
- SELECT appropriate second-line therapy based on chemotherapy-free intervals (CTFI)
- UNDERSTAND the potential role of emerging agents for SCLC, including MOA, safety, and monitoring
TARGET AUDIENCE
Oncologists, oncology nurses, community oncologists, community oncology nurse practitioners, community oncology physician assistants and community oncology nurses
FACULTY
Narjust Florez, M.D.
Thoracic Medical Oncologist
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Julia Kathleen Rotow, M.D.
Assistant Professor of Medicine
Dana-Farber Cancer Institute
DISCLOSURE OF FINANCIAL RELATIONSHIPS
The “Policy on Identification, Mitigation, and Disclosure of Relevant Financial Relationships” of Albert Einstein College of Medicine-Montefiore Medical Center requires that any individual in control of content, including faculty, participating in CME activities disclose to the audience all relevant financial relationships with ineligible companies* in the past 24 months. Any individual in control of content who refuses to disclose, or whose disclosed relationships prove to create a conflict of interest, will be recused.
Individuals with the absence of relevant financial relationships with ineligible companies will be disclosed to the audience.
All financial relationships of individuals in a position to control the content of this CME activity are identified and mitigated prior to the educational activity.
*The ACCME defines an ineligible company as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
ACCREDITED PROVIDER DISCLOSURE
The planners, and the Albert Einstein College of Medicine-Montefiore Medical Center staff for this educational activity have disclosed no relevant financial relationship(s) with an ACCME-defined ineligible company in the last 24 months.
Faculty Disclosure(s)
Narjust Florez, M.D. has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
Julia Kathleen Rotow, M.D. has no relevant financial relationships with ACCME-defined ineligible companies during the past 24 months.
PROVIDERSHIP
This educational activity is provided by Albert Einstein College of Medicine-Montefiore Medical Center.
ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and RealCME, LLC. Albert Einstein College of Medicine-Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CREDIT DESIGNATION STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center designates this other activity blended learning for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Credits
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category 1 credit for completing this program.
American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Program
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
DISCLOSURE OF UNLABELED USE
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a clinician relative to diagnostic and treatment options for a specific patient’s medical condition.
DISCLAIMER
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine-Montefiore Medical Center, RealCME or Jazz Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
METHOD OF PARTICIPATION/INSTRUCTIONS ON HOW TO RECEIVE CREDIT
Estimated time to complete this activity: 45 minutes
If you are seeking credit, you must complete the Post-Test and evaluation at the conclusion of the activity. Your certificate can be printed immediately.
PRIVACY STATEMENT
Albert Einstein College of Medicine-Montefiore Medical Center, Center for Continuing Professional Development (Einstein-Montefiore) protects the privacy of personal and other information regarding participants and education collaborators. Einstein-Montefiore will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting to the ACCME. Einstein-Montefiore maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of information collected from you.
COLLECTION AND USE OF YOUR PERSONAL INFORMATION
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, middle initial, degree, email address, address, and phone number. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected, retained, and used by Einstein-Montefiore to continuously improve the learning experience. Einstein-Montefiore will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Einstein-Montefiore will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
CONTACT INFORMATION
For questions regarding CME credit, contact Albert Einstein College of Medicine-Montefiore Medical Center at cme@montefiore.org.
For technical questions related to this activity, please contact support@realcme.com.
ACKNOWLEDGEMENT OF FINANCIAL SUPPORT
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |
